Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and ...

Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer ...

Fintel reports that on April 10, 2025, Scotiabank downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) from ...

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular ...

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

Scotiabank analyst George Farmer downgraded Tempest Therapeutics (TPST) to Sector Perform from Outperform with a reverse stock-split adjusted ...

HC Wainwright reaffirmed their neutral rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a report published on Thursday morning, Marketbeat reports. They currently have a $ ...

Tempest Therapeutics (TPST) announced that the company plans to explore a full range of strategic alternatives to advance its clinical stage ...

Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements. Shares rose 9.2% to $7.81 in ...